In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas

Laboratory Investigation

Volumn 93, Issue 11, 2013, Pages 1232-1240

  Bozzi, Fabio ^a   Conca, Elena ^a   Laurini, Erik ^b   Posocco, Paola ^b   Lo Sardo, Alessandra ^c   Jocollè, Genny ^a   Sanfilippo, Roberta ^a   Gronchi, Alessandro ^a   Perrone, Federica ^a   Tamborini, Elena ^a   Pelosi, Giuseppe ^a   Pierotti, Marco A ^a   Maestro, Roberta ^c   Pricl, Sabrina ^b   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

MDM2; MDMX; molecular modeling; Nutlin 3A; TP53

Indexed keywords

COMPLEMENTARY DNA; GLUTATHIONE TRANSFERASE; METHIONINE; NUTLIN 3; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; SULFUR 35; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; ISOPROTEIN; MDM2 PROTEIN, HUMAN; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG PROTEIN BINDING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPOSARCOMA; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADULT; AGED; ALTERNATIVE RNA SPLICING; ANTAGONISTS AND INHIBITORS; CELL DIFFERENTIATION; CHEMICAL STRUCTURE; COMPUTER SIMULATION; DRUG RESISTANCE; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MOLECULAR DYNAMICS; PATHOLOGY; PHYSIOLOGY; PROTEIN CONFORMATION; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; COMPUTER SIMULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DOSAGE; HUMANS; IMIDAZOLES; IN SITU HYBRIDIZATION, FLUORESCENCE; LIPOSARCOMA; MALE; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; NUCLEAR PROTEINS; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN CONFORMATION; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84886774775     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.107     Document Type: Article

References (38)

1. Mariñ o-Enŕquez A, Fletcher CD, Dal Cin P, et al. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcomalike) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria. Am J Surg Pathol 2010;34: 1122-1131.
2. Boland JM, Weiss SW, Oliveira AM, et al. Liposarcomas with mixed well-differentiated and pleomorphic features: a clinicopathologic study of 12 cases. Am J Surg Pathol 2010;34:837-843.
3. Singer S, Antonescu CR, Riedel E, et al. Istologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003;238:358-370.
4. Fletcher CDM, Bridge JA, Hegendoorn PCW, et al. World Health Organization Classification of Tumors of Soft Tissue and Bone. 4th edn, ( Lyon, 2013) pp37-38.
5. Butò S, Pierotti MA, Tamborini E, et al. Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection. Diagn Mol Pathol 1999;8:125-130. (Pubitemid 29521903)
6. Pilotti S, Della Torre G, Lavarino C, et al. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J Pathol 1997;181:14-24. (Pubitemid 27099769)
7. Pilotti S, Della Torre G, Lavarino C, et al. Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22. J Pathol 1998;185:188-190. (Pubitemid 28270932)
8. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303: 844-848. (Pubitemid 38174664)
9. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 Protein-Protein interaction to reactivate p53 function: a novel approach for cancer therapy. An Rev Pharmacol Toxicol 2009;49: 223-241.
10. Tamborini E, Della Torre G, Lavarino C, et al. Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas. Int J Cancer 2001;92:790-796. (Pubitemid 32467366)
11. Sigalas I, Calvert AH, Anderson JJ, et al. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996;2: 912-917. (Pubitemid 26296763)
12. Ito M, Barys L, O'Reilly T, et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res 2011;17: 416-426.
13. Seyfried I, Hofbauer S, Stoecher M, et al. SNP309 as a predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a. Blood 2008; 112:2168.
14. Malek SM. MDM2-SNP 309 allele does not affect sensitivity to MDM2 inhibitors in CLL. Blood 2008;112:2169.
15. Linares LK, Hengstermann A, Ciechanover A, et al. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA 2003;100:12009-12014. (Pubitemid 37271506)
16. Patton JT, Mayo LD, Singhi AD, et al. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006;66:3169-3176.
17. Hu B, Gilkes DM, Farooqi B, et al. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006;281: 3303-3305.
18. Rallapalli R, Strachan G, Tuan RS, et al. Identification of a domain within MDMX-S that is responsible for its high affinity interaction with p53 and high-level expression in mammalian cells. J Cell Biochem 2003;89:563-575. (Pubitemid 36648778)
19. Lenos K, Jochemsen AG. Functions of MDMX in the modulation of the p53-response. J Biomed Biotechnol 2011;2011:876173.
20. Lenos K, Grawenda AM, Lodder K, et al. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. Cancer Res 2012;72: 4074-4084.
21. Mü ller CR, Paulsen EB, Noordhuis P, et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 2007;121:199-205. (Pubitemid 46753868)
22. Bartel F, Schulz J, Böhnke A, et al. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int J Cancer 2005;117:469-475. (Pubitemid 41429571)
23. Tamborini E, Casieri P, Miselli F, et al. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. J Pathol 2007;212:227-235. (Pubitemid 46860154)
24. Piccinin S, Tonin E, Sessa S, et al. A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation. Cancer Cell 2012;22:404-415.
25. Poyurovsky MV, Katz C, Laptenko O, et al. The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 2010; 17:982-989.
26. Pierotti MA, Negri T, Tamborini E, et al. Targeted therapies: the rare cancer paradigm. Mol Oncol 2010;4:19-37.
27. Ferrone M, Perrone F, Tamborini E, et al. Functional analysis and molecular modeling show a preserved wild-type activity of p53 (C238Y). Mol Cancer Ther 2006;5:467-473.
28. Srinivasan J, Cheatham III TE, Cieplak P, et al. Continuum solvent studies of the stability of DNA, RNA, and phosphoroamidate-DNA helices. J Am Chem Soc 1998;120:9401-9409. (Pubitemid 28452628)
29. Isralewitz B, Gao M, Schulten K. Steered molecular dynamics and mechanical functions of proteins. Curr Opin Struct Biol 2001;11:224-230. (Pubitemid 32289426)
30. Ohnstad HO, Paulsen EB, Noordhuis P, et al. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines. BMC Cancer 2011;11:1-11.
31. Shaomeng W, Yujun Z, Denzil B, et al. Targeting the MDM2-p53 protein-protein interaction for new cancer therapeutics. Top Med Chem 2012;8:57-80.
32. Han X, Garcia-Manero G, McDonnell TJ, et al. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol 2007;20: 54-62. (Pubitemid 44967950)
33. Liang M, Han X, Vadhan-Raj S, et al. HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis. Mod Pathol 2010;23:381-391.
34. Valentin-Vega YA, Barboza JA, Chau GP, et al. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol 2007;38:1553-1562. (Pubitemid 47418967)
35. Mancini F, Conza GD, Moretti F. MDM4 (MDMX) and its transcript variants. Curr Genomics 2009;10:42-50.
36. Horvai AE, DeVries S, Roy R, et al. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol 2009;22:1477-1488.
37. Steinman HA, Burstein E, Lengner C, et al. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem 2004;279:4877-4886. (Pubitemid 38199083)
38. Graves B, Thompson T, Xia M, et al. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci USA 2012;109:11788-11793.